Navigation Links
Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

Researchers today presented preliminary safety and efficacy data for E7389 in the treatment of advanced, refractory breast cancer during the San Antonio Breast Cancer Symposium. E7389 is a synthetic analog of halichondrin B (HB), which is a natural product shown in preclinical studies to have highly potent anti-cancer activity in vitro and in vivo. Halichondrin B was originally isolated from a type of marine sponge.

This study was designed to evaluate E7389 as a monotherapy in patients with refractory breast cancer. The primary endpoint of this trial was response rate, measured using the RECIST (Response Evaluation Criteria In Solid Tumors) criteria ?a group of standards used to measure responses to treatment in solid tumors.

Of the 65 evaluable patients, 10 partial responses were confirmed at the 4th cycle assessment. Twenty-one patients had stable disease (SD). In treatment-refractory patients with advanced breast cancer this preliminary response rate (15%) appears promising.

Based on the preliminary results of this study, the predominant serious side effect related to E7389 was neutropenia (low white blood cell counts). Other side effects were considered mild to moderate and included nausea, fatigue, dehydration, arthralgias, dyspnea and neuropathy. None of the patients discontinued the study due to hematological toxicity.

"The results from this study with E7389 appear promising, and clinical research on E7389 as a treatment for breast cancer is continuing," said Sandra Silberman, MD, PhD, Associate Vice President and Global Therapeutic Area Head, Oncology at Eisai Medical Research Inc. "E7389 is an example of Eisai's human health care (hhc) commitment to satisfy unmet medical needs of patients and their families. Eisai has targeted oncology/critical care as one of three key therapeutic areas of focus," she added.

Seventy-one women were enrolled in the 28-day cycle patient group. Preliminary efficacy data for 65 patients
'"/>

Source:JFK Communcations


Page: 1 2

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. GlycoFi announces the first production of antibodies with human glycosylation in yeast
5. NHGRI announces new sequencing targets
6. CHAVI announces international search for genes affecting HIV response
7. NHGRI announces latest sequencing targets
8. MUHC announces a transplant first in Quebec
9. St. Jude announces breakthrough in eye cancer treatment
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials

Post Your Comments:
(Date:11/23/2009)...bridge, Mass. November 23, 2009 Applied mathemat...ly ( Hosta lancifolia ), a characteristic long lea...cked ripples along the edges. The simple cause of ...ing from bending during differential growthwas rev...hing foam ribbons. , Haiyi Liang, a postdoctoral...
(Date:11/23/2009)... study by the Wildlife Conservation Society says t...mp in the Republic of Congopart of the "mother lod...earare becoming increasingly threatened by growing...mmends protection of the swamp forests adjacent to...after recent surveys confirmed that high densities...
(Date:11/23/2009)...ton, CT Current research suggests that a common o...The related report by Nichols et al, "Unique Lipid...ass of TLR2 Ligands Capable of Enhancing Autoimmun...merican Journal of Pathology . , Multiple sclero...s the brain and spinal cord, affects nearly 1 in 7...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Factors from common human bacteria may trigger multiple sclerosis 2Tiny Batteries Can Cause Big Problems for Young Children 58870 1Tiny Batteries Can Cause Big Problems for Young Children 58870 2Pediatrics 3A Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 58868 1Pediatrics 3A Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 58868 2Pediatrics 3A Doctors Must Find Better Ways to Talk To Parents about Childhood Obesity 58868 38 Ounces a Day of POM Wonderful 100 25 Pomegranate Juice May Slow Progression of Carotid Intima Media Thickness 28CIMT 29 in Patients with Elevated C 58866 18 Ounces a Day of POM Wonderful 100 25 Pomegranate Juice May Slow Progression of Carotid Intima Media Thickness 28CIMT 29 in Patients with Elevated C 58866 28 Ounces a Day of POM Wonderful 100 25 Pomegranate Juice May Slow Progression of Carotid Intima Media Thickness 28CIMT 29 in Patients with Elevated C 58866 3
... important new study from the Journal of Consumer ...e parallel rise in obesity rates and the popularit...the researchers reveal that we over-generalize hea...ide dishes, and desserts containing up to 131% mor...althy. , In our black and white view, most food i...
...vernment priorities can drive local waste partners...d efficiency savings rather than wider sustainable...e Economic and Social Research Council shows. , R...ironmentally acceptable ways are significant issue...ublic service delivery, partnership working is a n...
...earchers may be able to tinker with a single amino...render them harmless, according to molecular biolo... a fast and cheap method of making vaccines., "We...ovirus," said Craig Cameron, the Paul Berg profess...tate. "And we think it is applicable to most other...
Other Biology News:You're likely to order more calories at a 'healthy' restaurant 2Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Discovery may help defang viruses 2Discovery may help defang viruses 3
(Date:11/19/2009)... , BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall...ovator in biotechnology for diabetes therapy, and ...services to food, supplement, biotechnology and ph...s of Tuesday,s Annual Meeting of Shareholders. ,...rated (Nasdaq: SPEX ) elected the following membe...
(Date:11/19/2009)... , MUNSTER, Germany, November 19 /PRNews... have filed on November 16th, 2009 Flibanserin in ... dyskinesia in Parkinson,s,disease for orphan drug...ency,(EMEA). Levodopa-induced dyskinesia is a comp...kinson,s and a serious burden to some of those,aff...
(Date:11/19/2009)... Top LASIK surgeons and recogn...d at Trusted LASIK Surgeons made brought their fel... in vision correction surgery, cataract surgery, a...ded American Academy of Ophthalmology (AAO) annual... Lindstrom, Dr. Shachar Tauber, Dr. David Huang, M...
(Date:11/19/2009)... InSound is honored by latest ... Newark, CA (PRWEB) November 16, 2009...ldquo;invisible” hearing aid from InSound Me... New Award in the Health category.  &nbs...s designed to reside deep in the hearing canal for...
Breaking Biology Technology:Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...O, Sept. 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ...t company,focused on commercializing proprietary p...infectious diseases, announced today that it has r...dministration (FDA) regarding its,proposed 505(b)(...ANX-514,(docetaxel emulsion). The FDA has indicate...
...A, Spain, Sept. 10 Elekta today unveiled a new,me...t the European Society,of Therapeutic Radiation On...iling ceremony in the Elekta booth, Elekta Preside...lekta Compact(TM), a new addition to,Elekta,s prod...y to,implement, more affordable solution for radia...
... Sept. 8 CeloNova BioSciences, Inc.,("CeloNova"),..., today,unveiled the world,s first fully color-cod...vanced Microspheres, at the annual meeting of the,...y of Europe (CIRSE) in,Athens, Greece. (Logo: ht... ) Embolic microspheres are used to treat liver ...
Other Biology Technology:ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 2ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 3ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 4Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability 2Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability 3CeloNova BioSciences Announces World's First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres 2
Biotin-OSu from Biosearch Technologies
Rat Anti-Mouse JAM-2 Monoclonal Antibody, Unconjugated from AbD Serotec
Normal Hamster Serum from Equitech-Bio
II Plate Washer (Plum) from GE Healthcare, formerly Amersham Biosciences
Biology Products: